Premium
Long‐term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single‐center experience
Author(s) -
Momose Mami,
Asahina Akihiko,
Umezawa Yoshinori,
Nakagawa Hidemi
Publication year - 2018
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.14145
Subject(s) - secukinumab , medicine , psoriatic arthritis , psoriasis , exacerbation , psoriasis area and severity index , single center , dermatology , clinical efficacy , clinical trial , arthritis , safety profile , adverse effect
Secukinumab is a fully human monoclonal antibody that can selectively neutralize interleukin‐17A, and its excellent efficacy has been demonstrated in clinical trials for psoriasis. The aim of our study is to assess long‐term efficacy and safety of secukinumab for 52 weeks in real‐world clinical practise in our facility. A total of 83 patients (71 with psoriasis vulgaris and 12 with psoriatic arthritis) were included, and 49 of them were bio‐switched patients. Psoriasis Area and Severity Index ( PASI ) 75 and PASI ‐90 responses were 80% and 64% at week 12, 77% and 65% at week 24, and 76% and 58% at week 52, respectively. No significant differences were observed in efficacy between bio‐naive and bio‐switched patients. Arthralgia showed improvement by week 12 in all patients with psoriatic arthritis with a reduction of serum C‐reactive protein level. Treatment was discontinued in 22% (18/83), including eight patients with no improvement or exacerbation of cutaneous manifestations, one patient with new onset of arthritis and two patients with transient infection. Overall, secukinumab showed a sustained clinical response with an acceptable safety profile through week 52 in Japanese psoriatic patients.